<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03577236</url>
  </required_header>
  <id_info>
    <org_study_id>CLIN-0050</org_study_id>
    <nct_id>NCT03577236</nct_id>
  </id_info>
  <brief_title>The Zenflow Spring System EU Safety and Performance Study</brief_title>
  <acronym>ZEST EU</acronym>
  <official_title>The Zenflow Spring System EU Safety and Performance Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zenflow, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zenflow, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of the trial are to demonstrate the safety and performance of the Zenflow
      Spring System in relieving the symptoms of obstructive Benign Prostatic Hyperplasia (BPH).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multi-center, prospective, single arm safety and performance trial. Subjects will be
      treated either in the Investigator's out-patient treatment room or in the OR, with local
      anaesthesia only. All subjects will be followed for the entire duration of the study until
      exit after the 24 month follow-up visit.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 16, 2019</start_date>
  <completion_date type="Anticipated">May 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Multi-center, prospective, single-arm.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Need for urinary catheterization</measure>
    <time_frame>7 days after the procedure</time_frame>
    <description>Rate of extended post-operative urinary catheterization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Successful placement of the Zenflow Spring Implant</measure>
    <time_frame>Day of discharge up to 7 days following device placement</time_frame>
    <description>Successful deployment and procedural success for the Zenflow System to implant the Spring device in the operating room or an out-patient clinical setting.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effectiveness of the Spring Implant in reducing symptoms of Benign Prostatic Hyperplasia (BPH) using the International Prostate Symptom Score and Quality of Life Score (IPSS+QoL)</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <description>The patient is asked to respond to 7 questions related to his urinary health using a rating scale of 0 to 5 where zero is excellent and 5 is the worst possible. The responses to the 7 questions are tallied for a total score. In addition the patient is asked 1 question related to his Quality of Life. The possible responses range from 0 to 6 where 0 is the best and 6 is the worst.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of procedure or device related serious adverse events</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Assessment of any device or procedure related Serious Adverse Events (SAE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Sexual Health Assessment: Change in sexual health measured by change in the Sexual Health Inventory for Men (SHIM) questionnaire score</measure>
    <time_frame>Baseline, 3, 6, 12, &amp; 24 months</time_frame>
    <description>The patient selects the most appropriate response to 5 questions about his sexual health. Each response has an assigned value between 1 and 5. The numeric values are tallied for a total score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Sexual Health Assessment: Change in sexual health measured by change in ability to ejaculate using the Male Sexual Health Questionnaire - Ejaculatory domain (MSHQ-EjD)</measure>
    <time_frame>Baseline, 3, 6, 12, &amp; 24 months</time_frame>
    <description>The patient selects the most appropriate response to 4 questions about his sexual health specific to ejaculation. Each response has an assigned value between 0 and 5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Pain, evaluated using a Visual Analog Score (VAS) of 1 to 10</measure>
    <time_frame>Baseline, 2 weeks, 1 month and 3 months</time_frame>
    <description>Patient describes pain on a Visual Analog Scale (VAS). The scale is a line labeled 1 at the far left indicating minimal pain and 10 on the right, which is maximum pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Adverse Events</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Rate of adverse events related to the procedure or device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness of the Spring Implant in reducing symptoms of Benign Prostatic Hyperplasia (BPH)</measure>
    <time_frame>Baseline, 2 weeks, 1, 6, 12, 24 months</time_frame>
    <description>The patient is asked to respond to 7 questions related to his urinary health using a rating scale of 0 to 5 where zero is excellent and 5 is the worst possible. The responses to the 7 questions are tallied for a total score. In addition the patient is asked 1 question related to his Quality of Life. The possible responses range from 0 to 6 where 0 is the best and 6 is the worst.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness of the Spring Implant in reducing symptoms of Benign Prostatic Hyperplasia (BPH)</measure>
    <time_frame>Baseline, 2 weeks, 1, 3, 6, 12, 24 months</time_frame>
    <description>Improvement in flow of urine as measured by uroflowmetry machine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness of the Spring Implant in reducing symptoms of Benign Prostatic Hyperplasia (BPH)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Incidence of repeat invasive treatment for Lower Urinary Tract Symptoms (LUTS) or increase in dosage or initiation of new medication to treat symptoms of BPH.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Zenflow Spring System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receives treatment with the investigational device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Zenflow Spring System</intervention_name>
    <description>The Zenflow Spring System consists of the Spring Delivery System with Implant, Spring Scope, Camera Control Unit (CCU), Measurement Tool, and Spring Retrieval Tool.</description>
    <arm_group_label>Zenflow Spring System</arm_group_label>
    <other_name>Spring Implant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient is able and willing to comply with all the assessments of the study

          2. Patient or patient's legal representative has been informed of the nature of the
             study, agrees to participate and has signed the informed consent form

          3. ≥ 45 years of age

          4. Baseline IPSS score &gt; 13, and a baseline Quality of Life (QoL) question score &gt; 3

          5. Prostate volume 25 - 80 cc by Trans Rectal Ultrasound (TRUS) or abdominal ultrasound,
             measured within past 90 days and prostatic urethral length between 2.5- 4.5 cm

          6. Failed, intolerant, or patient choice to not take a medication regimen for the
             treatment of LUTS

          7. Patient must meet ONE of the following criteria:

               1. Baseline PSA &lt;= 2.5ng/mL

               2. Baseline PSA &gt;2.5 ng/mL and &lt;=10 ng/mL AND free PSA &gt;=25% of total PSA (no biopsy
                  required or negative biopsy)

               3. Baseline PSA &gt;10ng/mL AND negative prostate biopsy1 result within 12 months

               4. Negative prostate biopsy1 within 12 months if abnormal digital rectal examination

               5. 3 Tesla MRI of the prostate, with normal findings, within 12 months prior to the
                  baseline visit

        Exclusion Criteria:

          1. Obstructive intravesical median prostatic lobe which, in the opinion of the
             Investigator, would not benefit from treatment

          2. Urethral stricture, meatal stenosis, or bladder neck obstruction - either current, or
             recurrent requiring 2 or more dilations as reported in the patient's history

          3. Requiring self-catheterization to void

          4. Baseline PSA &gt; 10 ng/mL or confirmed or suspected prostate cancer

          5. Any of the following, taken from a single uroflowmetry reading:

               1. Peak urinary flow rate &gt; 12 ml/second

               2. Post-void residual (PVR) &gt; 250 ml

               3. Peak Urinary flow rate of &gt; 15 ml/second

               4. &lt; 125ml urinary volume voided at baseline (pre-bladder urinary volume of ≥ 150 ml
                  required)

          6. Other condition or disease that might cause urinary retention

          7. History of other diseases causing voiding dysfunction

          8. Concomitant Urinary Tract Infection (UTI) (subject can be enrolled following
             successful treatment of UTI and a clean urine test), or a history of recurrent or
             chronic UTIs (defined as 2 or more UTIs in the past 12 months)

          9. Concomitant bladder stones

         10. Previous pelvic irradiation or radical pelvic surgery

         11. Previous prostate surgery, stent implantations, laser prostatectomy, hyperthermia or
             another invasive treatment to the prostate

         12. Chronic prostatitis, or recurring prostatitis within the past 12 months

         13. Known allergy to nickel

         14. Life expectancy less than 24 months

         15. Use of concomitant medications (e.g., anticholinergics, antispasmodics or
             antidepressants) affecting bladder function

         16. Inability to stop taking anticoagulants and/or antiplatelets for at least 3 days prior
             to the procedure or coumadin for at least 5 days prior to the procedure (low dose
             aspirin therapy not prohibited)

         17. Taking 5-alpha reductase inhibitors within 3 months of pre-treatment (baseline)
             evaluation unless evidence of same drug dose for at least 6 months with a stable
             voiding pattern (the drug dose should not be altered or discontinued throughout the
             study)

         18. Taking one of the following within 2 weeks of pre-treatment (baseline) evaluation:

               1. alpha-blockers,

               2. androgens,

               3. anticholinergics, or

               4. cholinergic medication gonadotropin releasing hormonal analogs

         19. Taking one of the following within 24 hours of pre-treatment (baseline) evaluation:

               1. phenylephrine, or

               2. pseudoephedrine

         20. Future fertility concerns

         21. Any severe illness that might prevent study completion or would confound study results
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Gilling, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tauranga Urology Research Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Debra Cogan, B.A., RN</last_name>
    <phone>+001 408 515-0820</phone>
    <email>dcogan@zenflow.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicholas Damiano, MS</last_name>
    <phone>+001 650 642-9658</phone>
    <email>Nick@zenflow.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Australian Clinical Trials</name>
      <address>
        <city>Wahroonga</city>
        <state>New South Wales</state>
        <zip>2076</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Penny Ombler</last_name>
      <phone>+61 2 9473 8765</phone>
      <email>research@urologist.net.au</email>
    </contact>
    <investigator>
      <last_name>Henry Woo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Coast Urology</name>
      <address>
        <city>Wollongong</city>
        <state>New South Wales</state>
        <zip>2500</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Edwards</last_name>
      <phone>+61 612 4271 6644</phone>
      <email>nurse@southcoasturology.com.au</email>
    </contact>
    <investigator>
      <last_name>Peter Chin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Goldfields Urology</name>
      <address>
        <city>Bendigo</city>
        <state>Victoria</state>
        <zip>3550</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janelle Brennan, Miss, MD</last_name>
      <phone>+61354413130</phone>
    </contact>
    <contact_backup>
      <last_name>Janet Bennett, CRA</last_name>
      <phone>+61354413130</phone>
      <email>janet_bennett@goldfieldsurology.com.au</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Verrelli</last_name>
      <phone>+61 613 9342 7348</phone>
      <email>richard.verrelli@mh.org.au</email>
    </contact>
    <investigator>
      <last_name>Paul Anderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urology Bay of Plenty</name>
      <address>
        <city>Tauranga</city>
        <zip>3140</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rana Reuther, CRA</last_name>
      <phone>64 7 577 7795</phone>
      <email>rana@urobop.co.nz</email>
    </contact>
    <contact_backup>
      <last_name>Peter Gilling, MD</last_name>
      <phone>64 7 579 0466</phone>
      <email>peter@urobop.co.nz</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>May 16, 2018</study_first_submitted>
  <study_first_submitted_qc>July 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2018</study_first_posted>
  <last_update_submitted>October 24, 2019</last_update_submitted>
  <last_update_submitted_qc>October 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

